Antibacterial Agents TRIZ Cases

Local quality principle modifies antibody hinge structure to increase blocking capability without compromising specificity for treating autoimmune diseases.

Copper-catalyzed cross-coupling synthesizes oxazolidinones without tin reagents, removing toxic impurities while maintaining antibacterial efficacy.

Selective heterocyclic amide antagonists target the EP4 receptor subtype to alleviate pain and inflammation while minimizing gastrointestinal toxicity.

Sulfated hydrogels resolve binding capacity versus selectivity trade-offs by controlling protein concentrations in complex fluids.

Cobalt porphyrin-phospholipid nanostructures bind polyhistidine-tagged peptides via coordination chemistry.

Open cell polyurethane foam prevents maggot escape and eliminates frequent wetting requirements.

Anti-inflammatory compounds activate adenosine receptors to block pro-inflammatory cytokines and prevent oxygen-induced lung injury.

Imidazolium oligomers disrupt microbial membranes physically to prevent resistance while preserving material integrity.

Cross-reactive antibodies bind IL-17A and IL-17F to inhibit pro-inflammatory cytokine activities.

A phenothiazinium photosensitizer combined with methylparaben and propylparaben generates singlet oxygen to destroy microbes.

Phosphorodiamidate morpholino oligomers resolve electrostatic repulsion and non-specific binding while maintaining nuclease degradation resistance.

Neutralizing adrenomedullin with specific antibodies stabilizes systemic circulation and reduces mortality risk in septic shock patients.

Histidine-rich glycoprotein agent boosts neutrophil phagocytosis strength to resolve bacterium clearance disorders in infectious diseases.

Reducing BAFF-R receptor activity with antagonists resolves the contradiction between rapid T cell proliferation and cost-effective manufacturing.

Aqueous Eruca sativa extract inhibits Gram-positive bacteria and mycoplasma growth through purified antimicrobial compounds.

Erythrocyte-encapsulated arginine deiminase overcomes short enzyme half-life and high toxicity to treat arginine-dependent tumors.

Novel 3-aminocarbonyl pyridine-1-oxide compounds inhibit p38 kinase activity to reduce cytokine production.

Unique tracer nucleic acid sequences enable precise detection of individual bacterial delivery vehicles in multivalent pharmaceutical mixtures.

Ionic association between antiseptics and antibiotics creates synergistic organic salts that resist beta-lactamase inactivation.

Novel dihydropyrimidinyl benzazepine carboxamide compounds act as specific TLR8 agonists.

Novel aromatic butan-2-ol compounds inhibit tubercle bacillus ATP synthetase, enabling shorter treatment cycles for drug-resistant tuberculosis.

Extracting active compounds into a fibrous matrix eliminates natural variability and heavy metal contamination while enabling consistent sublingual dosing.

A 1-benzoyl-N-(4-phenoxyphenyl)piperidine-3-carboxamide compound inhibits PD-L1 expression and reduces IL-2 production.

Distinct XRPD patterns identify stable Tiacumicin B polymorphs, resolving contradictions between dissolution rates and long-term storage reliability.

Targeting IRAK4 kinase reduces inflammatory cytokines and cell infiltration, mitigating lung tissue damage while avoiding broad immunosuppression.

A selective androgen receptor modulator compound delivers tissue-specific anabolic effects through targeted molecular binding mechanisms.

Novel tricyclic compounds overcome multi-drug resistance barriers to shorten tuberculosis treatment duration.

Hydroxamic acid compounds target gelatinases MMP-2 and MMP-9 to minimize secondary effects from non-selective inhibition.

5-Alkynyl-pyrimidine compounds inhibit PI3Kα and mTOR kinases, resolving incomplete pathway inhibition caused by single-target therapies.

Amyloid precursor protein signal peptides provide broad antimicrobial spectra while reducing drug resistance risks through novel sequence diversity.

N-(1-(2-aminoethyl)-1H-tetrazol-5-yl)-3-chlorobenzamide derivatives inhibit the ClpXp protease enzyme to block bacterial growth.

Aerosolized levofloxacin delivers targeted antibiotic therapy to pulmonary sites.

Segmenting viral vector and yeast platforms overcomes limited cell-mediated immunity by inducing diverse T-cell responses.

Optimizing copper ion concentration and pH activates formylglycine-generating enzymes, enabling efficient site-specific conjugation of therapeutic agents.

Formula I N-chlorinated cationic compounds deliver targeted antimicrobial efficacy while minimizing toxicity to mammalian cells.

Modified inositol compounds activate C. difficile toxins in high calcium colon environments without precipitation.

A synbiotic preparation combines specific oligosaccharides with probiotic strains to support infant gut health.

Vinyl isocyanide compounds eradicate established microbial biofilms at sub-minimum inhibitory concentrations.

A sol-gel process creates metal oxide shells around core materials using nanoparticle incorporation.

Inhibitory peptides bind Staphylococcus aureus leukotoxins to block immune cell receptor interactions, preventing antibiotic-resistant bacterial virulence.

Lactobacillus paracasei counters antibiotic-induced dysbiosis by clearing pathogens and restoring microbiota diversity.

Combining quaternary ammonium salts with pyrithione expands the antimicrobial spectrum while lowering required concentrations.

Anti-AIP2 antibodies target the agr operon to block quorum sensing, reducing biofilm formation and antibiotic resistance development.

Citric acid and surfactant coatings on polypropylene masks bind pathogens chemically, resolving fit gaps that allow airborne particle ingress.

Modular peptide macrocycles overcome antibiotic resistance in Acinetobacter baumannii by targeting multiple bacterial surface sites simultaneously.

Histidine kinase inhibitors disrupt bacterial signaling networks to reduce virulence without inducing antibiotic resistance.